Key result
Platinum single-molecule sequencer distinguishes paralogous TPM peptides, tissue-specific spliceforms, and phosphotyrosine modifications.
Why the study?
Human tropomyosin genes produce similar proteoforms that can be challenging to distinguish with standard proteomics tools.
Next-generation single-molecule protein sequencing can distinguish highly similar tropomyosin proteoforms, including single amino acid substitutions and post-translational modifications, paving the way for targeted biomarker detection.
May enable proteoform-specific tropomyosin research; leaves open human validation and clinical translation.
Protein variants of the same gene─proteoforms─can have high molecular similarity yet exhibit different biological functions. Thus, the identification of unique peptides that unambiguously map to proteoforms can provide crucial biological insights. In humans, four human tropomyosin (TPM) genes produce similar proteoforms that can be challenging to distinguish with standard proteomics tools. For example, TPM1 and TPM2 share 85% sequence identity with amino acid substitutions that play unique roles in muscle contraction and myopathies. In this study, we evaluated the ability of the recently released Platinum single-molecule protein sequencer to detect proteoform-informative peptides. Platinum employs fluorophore-labeled recognizers that reversibly bind to cognate N-terminal amino acids (NAAs), enabling polypeptide sequencing within nanoscale apertures of a semiconductor chip that can accommodate single peptide molecules. As a proof of concept, we evaluated the ability of Platinum to distinguish three main types of proteoform variation: paralogue-level, transcript-level, and post-translational modification (PTM). We distinguished paralogous TPM1 and TPM2 peptides differing in a single isobaric residue (leucine/isoleucine). We also distinguished tissue-specific TPM2 spliceforms. Notably, we found that a phosphotyrosine-modified peptide displayed a reduced recognizer affinity for tyrosine, showing sensitivity to PTMs. This study paves the way for the targeted detection of proteoform biomarkers at the single molecule level.
No takes yet. Share an insight, caveat, or question.
Sittipongpittaya et al. (2025) studied this question. Platinum single-molecule protein sequencer (NGPS) was evaluated on Differentiation of proteoform-informative peptides (paralogue, spliceform, and PTM variants). The Platinum single-molecule protein sequencer successfully distinguished paralogous TPM1 and TPM2 peptides differing by a single isobaric residue, tissue-specific spliceforms, and phosphotyrosine modifications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: